Trial of rucaparib in prostate indications 2 (TRITON2): An international, multicentre, open-label phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Meeting Abstract


Authors: Shapiro, J.; Voskoboynik, M.; Krieger, L.; Byard, I.; Clay, T.; Ganju, V.; Abida, W.; Chowdhury, S.; Watkins, S.; Despain, D.; Simmons, A.; Go, J.; Golsorkhi, T.; Scher, H. I.
Abstract Title: Trial of rucaparib in prostate indications 2 (TRITON2): An international, multicentre, open-label phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Meeting Title: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Annual Scientific Meeting 2017
Journal Title: Asia-Pacific Journal of Clinical Oncology
Volume: 13
Issue: Suppl. 1
Meeting Dates: 2017 Jul 16-18
Meeting Location: Melbourne, Australia
ISSN: 1743-7555
Publisher: Wiley Blackwell  
Date Published: 2017-07-01
Start Page: 61
Language: English
ACCESSION: WOS:000427541700107
PROVIDER: wos
DOI: 10.1111/ajco.12719
Notes: Meeting Abstract: 163 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
  2. Wassim Abida
    158 Abida